The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS)

摘要 以芝加哥为中心，这是一个最多样化但又最隔离的城市之一，拥有一些最引人注目的健康 美国P20发展西北大学癌症的可行性及规划建议 健康公平研究孢子将产生科学发现并建立可持续的、 协作、学术和社区基础设施，将作为全面 转化型癌症研究计划侧重于妇科癌症的健康差异。在这份提案中，我们设置了 我们最初的翻译研究重点是Black经历的子宫内膜癌和卵巢癌的差异 女人。NU-cher P20项目利用了西北大学杰出的翻译研究能力 大学及其国家癌症研究所指定的罗伯特·H·卢里综合癌症中心。研究项目1 通过肿瘤基因组学研究子宫内膜癌的种族差异。调查结果将产生关键 这些信息不仅加深了我们对子宫内膜肿瘤的生物学种族差异的理解 但可用作对治疗反应的种族差异的预测性指标。研究项目2 重点关注卵巢癌DNA甲基化事件的种族差异，这可能会影响对 以铂为基础的卵巢癌治疗，并解释Black经历的生存显著差异 女人。这项研究将确定黑人和白人女性高级别浆液性卵巢癌的甲基组 以及开发高级别浆液性卵巢癌患者来源的异种移植物(PDX)和有机类化合物 这些模型对铂的反应将在体外和体内进行评估。调查结果将定义 途径和基因受表观遗传调控，这可能解释了临床结果的差异，并可能 成为干预的相关目标。支持这些项目并为未来建立坚实的基础设施 资助妇科癌症健康差异P50孢子，我们提出两个核心。管理核心(AC) 是科学、财政和行政监督和综合的协调中心。妇科生物医学 病理核心(GBPC)将为当前和未来的医院项目维护组织/血液储存库， 与小约翰·H·斯特罗格合作。库克县医院加强少数民族可获得性 NU研究人员可获得的妇科生物标本。此外，我们还提出了一个发展性的 支持大学基础设施发展目标和翻译管道的研究计划(DRP) 卓越的研究成果。NU-cher P20团队由基础研究人员、翻译研究人员和临床研究人员组成 协同优势准备打造一个持久的翻译研究计划，专注于理解和 缩小妇科癌症差距。

ABSTRACT Centered in Chicago, one of the most diverse yet segregated cities with some of the most striking health disparities in the US, this P20 feasibility and planning proposal to develop the Northwestern University Cancer Health Equity Research SPORE (NU-CHERS) will generate scientific findings and establish sustainable, collaborative, academic and community infrastructure that will serve as the foundation for a comprehensive translational cancer research program focused on gynecologic cancer health disparities. In this proposal, we set our initial translational research focus on endometrial and ovarian cancer disparities as experienced by Black women. This NU-CHERS P20 program leverages outstanding translational research capacity at Northwestern University and its NCI-designated Robert H. Lurie Comprehensive Cancer Center. Research Project 1 investigates racial disparities in endometrial cancer through tumor genomics. Findings will generate critical information that not only deepens our understanding of the biological racial differences in endometrial tumors but can be used as a predictive measure for racial differences in response to treatments. Research Project 2 focuses on racial differences in DNA methylation events in ovarian cancer which may impact response to platinum-based ovarian cancer treatment and explain the striking disparity in survival experienced by Black women. The study will define the methylomes of high-grade serous ovarian cancer in Black and White women as well as develop high-grade serous ovarian cancer-derived patient derived xenografts (PDX) and organoids from which response of these models to platinum will be assessed in vitro and in vivo. Findings will define pathways and genes regulated epigenetically, which could account for disparity in clinical outcomes and may become relevant targets for intervention. To support these projects and build a solid infrastructure for a future funded gynecologic cancer health disparities P50 SPORE, we propose two Cores. The Administrative Core (AC) is the focal point for scientific, fiscal and administrative oversight and integration. The Gynecologic Biospecimen Pathology Core (GBPC) will maintain tissue/blood repositories for current and future NU-CHERS projects, in partnership with the John H. Stroger, Jr. Hospital of Cook County to enhance the availability of minority gynecologic biospecimens available to NU-CHERS researchers. In addition, we propose a Developmental Research Program (DRP) to support NU-CHERS infrastructure development goals and pipeline of translational research excellence. The NU-CHERS P20 team is comprised of basic, translational, and clinical investigators with synergistic strengths poised to forge a lasting translational research program focused on understanding and reducing gynecologic cancer disparities.